Tumor markers for bladder cancer: outlook for routine use

被引:0
作者
Ecke, Thorsten H. [1 ]
机构
[1] HELIOS Klinikum Bad Saarow, Urol Klin, D-15526 Bad Saarow Pieskow, Germany
来源
LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE | 2010年 / 34卷 / 02期
关键词
bladder cancer; tumor marker; urothelial cell carcinoma; TRANSITIONAL-CELL CARCINOMA; TISSUE POLYPEPTIDE ANTIGEN; IN-SITU HYBRIDIZATION; GROWTH-FACTOR RECEPTOR-3; CARE PROTEOMIC ASSAY; TP53; GENE-MUTATIONS; URINARY-BLADDER; FOLLOW-UP; CLINICAL-IMPLICATIONS; UROTHELIAL CARCINOMA;
D O I
10.1515/JLM.2010.021
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
This article outlines the role of bladder cancer tumor markers in diagnosis and therapy with a particular focus on the most important biomarkers. A MEDLINE based literature search was performed to examine the field of bladder cancer markers. Further determination of recurrence and progression markers will contribute to establish better treatments for the individual patient. Molecular staging of urological tumors will allow selecting cases that will require systemic treatment. Therapeutically, knowledge of cancer progression pathways allows for drug therapies against specific tumor targets. It is necessary and important to integrate under the same objectives basic translational and clinical research.
引用
收藏
页码:77 / 86
页数:10
相关论文
共 94 条
  • [41] Lonn U, 1995, CLIN CANCER RES, V1, P1189
  • [42] Usefulness of tissue polypeptide antigen in the follow-up of bladder cancer
    López, VM
    Galán, JA
    Fernández-Suárez, A
    López-Celada, S
    Alcover, J
    Filella, X
    [J]. UROLOGY, 2003, 62 (02) : 243 - 248
  • [43] Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review and meta-analyses
    Lotan, Y
    Roehrborn, CG
    [J]. UROLOGY, 2003, 61 (01) : 109 - 118
  • [44] Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: A decision analytical approach
    Lotan, Y
    Roehrborn, CG
    [J]. JOURNAL OF UROLOGY, 2002, 167 (01) : 75 - 79
  • [45] MAULARD C, 1994, CANCER, V73, P394, DOI 10.1002/1097-0142(19940115)73:2<394::AID-CNCR2820730226>3.0.CO
  • [46] 2-Y
  • [47] Serum tissue polypeptide antigen in bladder cancer as a tumor marker: A prospective study
    MaulardDurdux, C
    Toubert, ME
    Hennequin, C
    Housset, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (12) : 3446 - 3450
  • [48] C-erbB-2 in bladder cancer: Molecular biology, correlation with epidermal growth factor receptors and prognostic value
    Mellon, JK
    Lunec, J
    Wright, C
    Horne, CHW
    Kelly, P
    Neal, DE
    [J]. JOURNAL OF UROLOGY, 1996, 155 (01) : 321 - 326
  • [49] HOME SCREENING FOR HEMATURIA - RESULTS OF A MULTICLINIC STUDY
    MESSING, EM
    YOUNG, TB
    HUNT, VB
    ROECKER, EB
    VAILLANCOURT, AM
    HISGEN, WJ
    GREENBERG, EB
    KUGLITSCH, ME
    WEGENKE, JD
    [J]. JOURNAL OF UROLOGY, 1992, 148 (02) : 289 - 292
  • [50] COMPARISON OF BLADDER-CANCER OUTCOME IN MEN UNDERGOING HEMATURIA HOME SCREENING VERSUS THOSE WITH STANDARD CLINICAL PRESENTATIONS
    MESSING, EM
    YOUNG, TB
    HUNT, VB
    GILCHRIST, KW
    NEWTON, MA
    BRAM, LL
    HISGEN, WJ
    GREENBERG, EB
    KUGLITSCH, ME
    WEGENKE, JD
    [J]. UROLOGY, 1995, 45 (03) : 387 - 396